Yahng Seung-Ah, Jeon Young-Woo, Yoon Jae-Ho, Shin Seung-Hwan, Lee Sung-Eun, Cho Byung-Sik, Eom Ki-Seong, Kim Yoo-Jin, Lee Seok, Min Chang-Ki, Cho Seok-Goo, Kim Dong-Wook, Lee Jong-Wook, Min Woo-Sung, Kim Hee-Je
Department of Hematology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Catholic Blood and Marrow Transplantation Center, Department of Hematology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Biol Blood Marrow Transplant. 2016 Feb;22(2):316-323. doi: 10.1016/j.bbmt.2015.09.018. Epub 2015 Sep 28.
This study explored the influence of mismatched inhibitory killer cell immunoglobulin-like receptor (KIR) ligands on the outcome of haploidentical transplantation using T cell-replete, granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in adult patients with acute myeloid leukemia (AML). Three groups were examined: unidirectional graft-versus-host KIR ligand mismatched (GVH-KIR-MM; n = 33), bidirectional KIR ligand matched (KIR-M; n = 41), and unidirectional host-versus-graft KIR ligand mismatched (HVG-KIR-MM; n = 26). All recipients were treated with the same conditioning regimen (800 cGy total body irradiation, fludarabine, busulfan, and antithymocyte globulin). After a median follow-up of 26 months, the 2-year cumulative incidence of relapse was significantly higher in HVG-KIR-MM (40.3% ± 10.3%) versus others (18.9% ± 4.8%, P = .044). In the standard-risk group, the 2-year disease-free survival (DFS) was significantly lower in HVG-KIR-MM (51.8% ± 11.2%) compared with GVH-KIR-MM (88% ± 8.1%, P = .025). Multivariate analysis showed that HVG-KIR-MM was significantly associated with higher relapse (hazard ratio [HR], 10.7; P = .002) and lower DFS (HR, 3.4; P = .012). Subgroup analysis revealed increased DFS with higher doses of CD3(+)CD8(+) and CD3(-)CD56(+) grafts in GVH-KIR-MM (90.9% ± 8.7%, P = .006); there was no such effect in the other groups. Although our conclusions are limited by the absence of donor KIR genotype data, our study suggests unidirectional KIR ligand incompatibility in the host-versus-graft vector has a detrimental effect on T cell-replete haploidentical transplantation outcomes in adult patients with AML.
本研究探讨了错配抑制性杀伤细胞免疫球蛋白样受体(KIR)配体对成年急性髓系白血病(AML)患者采用富含T细胞、粒细胞集落刺激因子动员的外周血干细胞进行单倍体移植结局的影响。研究了三组:单向移植物抗宿主KIR配体错配(GVH-KIR-MM;n = 33)、双向KIR配体匹配(KIR-M;n = 41)和单向宿主抗移植物KIR配体错配(HVG-KIR-MM;n = 26)。所有受者均接受相同的预处理方案(全身照射800 cGy、氟达拉滨、白消安和抗胸腺细胞球蛋白)。中位随访26个月后,HVG-KIR-MM组的2年累积复发率(40.3%±10.3%)显著高于其他组(18.9%±4.8%,P = 0.044)。在标准风险组中,HVG-KIR-MM组的2年无病生存率(DFS)(51.8%±11.2%)显著低于GVH-KIR-MM组(88%±8.1%,P = 0.025)。多因素分析显示,HVG-KIR-MM与较高的复发率(风险比[HR],10.7;P = 0.002)和较低的DFS(HR,3.4;P = 0.012)显著相关。亚组分析显示,在GVH-KIR-MM组中,较高剂量的CD3(+)CD8(+)和CD3(-)CD56(+)移植物可提高DFS(90.9%±8.7%,P = 0.006);其他组未观察到这种效果。尽管我们的结论因缺乏供体KIR基因型数据而受到限制,但我们的研究表明宿主抗移植物方向的单向KIR配体不相容性对成年AML患者富含T细胞单倍体移植结局有不利影响。